Literature DB >> 23341429

Contradictory results with high-dosage rifamycin in mice and humans.

A R M Coates, Yanmin Hu, A Jindani, D A Mitchison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23341429      PMCID： PMC3553725          DOI： 10.1128/AAC.01705-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

1.  Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Authors:  Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Ming Zhang; Deepak Almeida; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

3.  Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum.

Authors:  Galina V Mukamolova; Obolbek Turapov; Joanne Malkin; Gerrit Woltmann; Michael R Barer
Journal:  Am J Respir Crit Care Med       Date:  2009-10-29       Impact factor: 21.405

4.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

5.  Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins.

Authors:  D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2012-07-12       Impact factor: 2.373

6.  Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Authors:  Susan E Dorman; Stefan Goldberg; Jason E Stout; Grace Muzanyi; John L Johnson; Marc Weiner; Lorna Bozeman; Charles M Heilig; Pei-Jean Feng; Ruth Moro; Masahiro Narita; Payam Nahid; Susan Ray; Edward Bates; Betial Haile; Eric L Nuermberger; Andrew Vernon; Neil W Schluger
Journal:  J Infect Dis       Date:  2012-07-30       Impact factor: 5.226

7.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

8.  Mycobacterium tuberculosis from chronic murine infections that grows in liquid but not on solid medium.

Authors:  Jasvir Dhillon; Douglas B Lowrie; Denis A Mitchison
Journal:  BMC Infect Dis       Date:  2004-11-17       Impact factor: 3.090
  8 in total
  6 in total

1.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

2.  Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Authors:  Eric L Nuermberger; Ian M Rosenthal; Rokeya Tasneen; Charles A Peloquin; Khisimuzi E Mdluli; Petros C Karakousis; Jacques H Grosset
Journal:  Antimicrob Agents Chemother       Date:  2013-02       Impact factor: 5.191

Review 3.  A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.

Authors:  Véronique Dartois; Clifton E Barry
Journal:  Bioorg Med Chem Lett       Date:  2013-07-12       Impact factor: 2.823

4.  High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo.

Authors:  Yanmin Hu; Alexander Liu; Fatima Ortega-Muro; Laura Alameda-Martin; Denis Mitchison; Anthony Coates
Journal:  Front Microbiol       Date:  2015-06-23       Impact factor: 5.640

5.  Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies.

Authors:  Pia Abel Zur Wiesch; Fabrizio Clarelli; Ted Cohen
Journal:  PLoS Comput Biol       Date:  2017-01-06       Impact factor: 4.475

6.  Phenotypically Adapted Mycobacterium tuberculosis Populations from Sputum Are Tolerant to First-Line Drugs.

Authors:  Obolbek Turapov; Benjamin D O'Connor; Asel A Sarybaeva; Caroline Williams; Hemu Patel; Abdullaat S Kadyrov; Akpay S Sarybaev; Gerrit Woltmann; Michael R Barer; Galina V Mukamolova
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.